The abstract is read at the publisher; the summary is JClub's.
In 14 patients with Sézary syndrome on mogamulizumab, CD39/CD73/CD38 ectonucleotidase profiles on CD4+ T cells track hematologic disease activity, declining with response and returning at relapse.
- Why it matters: Reliable pharmacodynamic biomarkers are lacking for monitoring treatment response and relapse in Sézary syndrome, and understanding immune remodeling during therapy could improve biomarker-driven management.
- What they did: Peripheral blood immune subsets were longitudinally profiled by 6-color and 22-color flow cytometry over a median 26-month follow-up, measuring ectonucleotidase expression on malignant and non-malignant subsets through response and relapse.
- The result: Responders showed persistently low CD38 with retained patient-specific CD39 and/or CD73 aberrant profiles, while cutaneous-only progression kept stable circulating ectonucleotidase profiles; mogamulizumab also induced immune remodeling, including CD39+ regulatory T-cell re-expansion in selected progressors and unchanged profiles in primary resistance.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.